Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

Exclusion Criteria

• •Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
• •Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
• •White blood cell (WBC) \< 4,000.
• •Platelet count \< 100,000.
• •Total serum bilirubin \> 2 mg/dL.
• •Serum creatinine \> 2 mg/dL.
• •Alkaline phosphatase \> 3 times the upper normal limit.
• •Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) \> 3 times the upper normal limit.
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• •Pregnant or nursing female subjects.
• •Unwilling or unable to follow protocol requirements.
• •Any condition which in the investigator?s opinion deems the subject an unsuitable candidate to receive porfimer sodium.
• •Received an investigational agent within 30 days prior to enrollment.